protein subunit: Novavax COVID-19 vaccine

ApprovedVaccine

protein subunit: Novavax COVID-19 vaccine is one of 19 biologic programs targeting COVID-19. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Approved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

protein subunit: Novavax COVID-19 vaccine

NNovavax

Approved

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Singulair

AstraZeneca

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Active, not recruiting·NNovavax·Phase 4·NCT06633835·660 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for protein subunit: Novavax COVID-19 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — protein subunit: Novavax COVID-19 vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for protein subunit: Novavax COVID-19 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novavax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: NNovavax

protein subunit: Novavax COVID-19 vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

References

Drug Info

Quick Facts

Related News